摘要
目的 :观察低分子肝素钠与降纤酶联合治疗UAP的疗效与安全性。方法 :对 45例UAP常规抗心绞痛用药的基础上 ,应用低分子肝素钠 50 0 0U腹壁皮下注射q12h ,共 5d ,,降纤 10U加入生理盐水 10 0mL静脉滴注 ,应用 10d ,用药前后对比观察血液流变学 ,心电图及心绞痛发作次数和程度。结果 :缓解心绞痛有效率 ,起效 (减轻 )天数和消失天数对照组与治疗组比较 ,依次为 77%与 95% ,6± 9d与 4± 5d(P <0 0 5) ,后者且有改善心肌缺血 ,提高心功能的作用、副作用少。结论 :低分子量肝素钠与降纤酶联合治疗UAP有效安全。
Objective:To observe the effect and safety of low-molec ular-weight,heparin natrum and defibrase in treatment of UAP.Methods: 88 cases with UAP were divided randomly into two groups.The first group,43 cases as control who treated with β-blocker,calcium antagonists and one kind of iso sorbide dinitrate.The second group,45 cases added subcutaneous deeply injection of low-moducular-weight 5000U q12h used for 5 days and defibrase 10U was given in 0.9% normal saline 100mL intravenous drip for 10 days,Hemddynamics ch anges.ECG and times or severity of angina pectoris attaches.Results: The total effect rate in the treatment group was better than that in the control group (P<0.05).At the same time,the myolardial ischemic or cardiac functio n improved in the treatment group,and few adverse effects were found.Concl usion:It is effective and safe therapy that the UAP is treated by low-mol ecular-weight heparin natrum combined with defibrase.
出处
《医学理论与实践》
2003年第11期1241-1242,共2页
The Journal of Medical Theory and Practice
